Eli Lilly's COVID-19 antibody shows it can prevent the disease. But will doctors use it?


Eli Lilly’s bamlanivimab was the first antibody-drug the FDA authorized to treat COVID-19. Now, the Indianapolis pharma has data showing the therapy prevents symptomatic infections.


The catch? The data are limited to long-term care facilities, where vaccination is now underway—and despite their utility, antibody therapies are having a tough time catching on.


Check out this article published by Fierce Pharma right here.

0 comments

© 2021 by Covid Plasma Initiative Foundation

The Yitzchok Lebovits COVID Plasma Initiative is dedicated in memory of R’ Yitzchok a"h Ben R’ Moshe Eliezer y"blt, who recently passed away. R' Yitzchok was a brother of Chaim Lebovits who has been a driving force behind every aspect of this initiative to bring this life-saving therapy to the people who need it.